Concierge Medicine: Benefits, Costs, and What to Know
Ozempic and cardiovascular risk: New Findings Demand Closer scrutiny
What Happened? A closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death – in adults with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo.The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated significant weight loss,the cardiovascular safety signal is prompting a reassessment of its use in this specific patient population.
Key Findings: The Numbers Tell the Story
The study found that 6.5% of patients taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33, indicating a 33% increased risk. Importantly, the weight loss achieved with semaglutide – an average of approximately 15% of initial body weight – did *not* appear to offset this cardiovascular risk. The findings were particularly pronounced in patients with a history of heart failure.
| Event | Semaglutide Group (%) | Placebo Group (%) |
|---|---|---|
| Cardiovascular Death | 1.5% | 1.2% |
| Non-Fatal Stroke | 1.7% | 1.3% |
| Non-Fatal Heart Attack | 3.4% | 2.4% |
| MACE (Combined) | 6.5% | 4.9% |
Who is Affected? Understanding Patient Risk
These findings primarily impact individuals with obesity *and* pre-existing cardiovascular disease. This includes those with a history of heart attack, stroke, peripheral artery disease, or heart failure. The trial did *not* include patients with type 2 diabetes,raising questions about weather the cardiovascular risk profile differs in that population. Individuals without established heart disease likely face a different risk-benefit calculation, but further research is needed to clarify this.
It’s crucial to differentiate between correlation and causation. While the SELECT trial demonstrates an association between semaglutide and increased cardiovascular events,it doesn’t definitively prove that the drug *caused* these events. Other factors, such as underlying health conditions and lifestyle choices, could contribute.
Why Does this Matter? The Shifting Landscape of Obesity Treatment
Semaglutide, marketed as Ozempic and Wegovy, has been hailed as a breakthrough in obesity treatment, offering substantial weight loss benefits. However, the SELECT trial introduces a critical caveat: its use in patients with established cardiovascular disease may not be as straightforward as previously thought. This challenges the narrative of semaglutide as a universally beneficial drug and underscores the importance of individualized risk assessment.